Sodium Oxybate: Uses, How It Works, and Side Effects

Sodium oxybate is a prescription central nervous system depressant used primarily to treat narcolepsy, where it reduces cataplexy attacks and excessive daytime sleepiness while consolidating fragmented nighttime sleep. Chemically, it is the sodium salt of gamma-hydroxybutyrate (GHB), a compound with a complicated reputation due to decades of illicit use and abuse. Prescribed under tightly controlled distribution programs, sodium oxybate works in a way that sounds paradoxical: a sedative taken at night that makes people more alert during the day. The explanation involves an unusual effect on brain chemistry that plays out over hours, and the drug’s clinical story extends well beyond narcolepsy.

How Sodium Oxybate Works in the Brain

The mechanism behind sodium oxybate is not fully pinned down, but the leading explanation centers on how it manipulates dopamine, the neurotransmitter closely tied to wakefulness and motivation. When the drug is active in the body, it initially suppresses dopamine release from neurons. During this suppression phase, dopamine accumulates inside the cells rather than being released into the surrounding tissue. Once the drug clears, that stored dopamine floods out in a rebound burst. In laboratory experiments on brain tissue, this biphasic pattern is clear: dopamine release drops for several minutes and then rises above baseline levels as the stored transmitter is let go.

In clinical terms, this translates into a two-phase cycle. The drug is taken at bedtime, so the dopamine-suppressing phase coincides with the hours when sleep is needed, deepening and stabilizing it. By the time morning arrives and drug levels have fallen, the accumulated dopamine is released, promoting wakefulness. This hypothesis explains one of sodium oxybate’s most valued properties: it treats both nighttime sleep disruption and daytime sleepiness with a single medication, rather than needing separate drugs for each.

Effects on Sleep Architecture

People with narcolepsy tend to have severely fragmented nighttime sleep. They cycle too quickly between sleep stages, wake up repeatedly, and spend too little time in deep slow-wave sleep, the restorative stage that healthy sleepers spend substantial time in during the first half of the night. Sodium oxybate directly addresses this pattern. In clinical studies, it produces dose-related increases in slow-wave sleep and in the specific brainwave power associated with deep sleep, while reducing the number of awakenings and transitions into lighter sleep stages.

The consolidation effect is measurable. In a placebo-controlled study, the number of shifts from deeper sleep stages to light sleep or wakefulness dropped significantly at higher doses, with the 9-gram dose outperforming placebo across every category of sleep disruption measured.

⁴

Stage 1 sleep, the lightest and least restorative stage, also decreases. Wake after sleep onset drops. Total sleep time increases. All of these changes scale with the dose, meaning that a clinician can titrate the medication upward until sleep quality reaches a satisfactory level.

⁵

This improvement is not just a narcolepsy phenomenon. In a controlled study of sleep-deprived healthy adults, those given sodium oxybate had more slow-wave sleep and greater deep-sleep brainwave activity during recovery sleep compared to placebo, and they performed better on subsequent waking tasks. The drug genuinely deepens sleep in a measurable, functional way.

⁶

Treating Cataplexy

Cataplexy, the sudden loss of muscle tone triggered by emotions like laughter or surprise, is the hallmark symptom of narcolepsy type 1 and one of the most disabling features of the disease. Sodium oxybate is one of the most effective treatments available for it. In a large double-blind trial of 228 patients, nightly doses of 4.5, 6, and 9 grams produced median reductions in weekly cataplexy attacks of roughly 57%, 65%, and 85%, respectively, compared to placebo.

⁷

An earlier dose-ranging trial confirmed the pattern, with the 9-gram dose reaching statistical significance for cataplexy reduction while the 6-gram dose approached it.

⁸

The effect on daytime sleepiness is equally important. In a head-to-head design where patients already stabilized on modafinil (a standard wakefulness-promoting drug) were switched to sodium oxybate alone, placebo, or the combination, sodium oxybate by itself maintained the same level of wakefulness that modafinil had been providing. The combination of both drugs went further, increasing daytime sleep latency from about 10 minutes to over 13 minutes on the Maintenance of Wakefulness Test.

⁹

Sodium oxybate also does something modafinil does not: it consolidates nighttime sleep. In a study directly comparing their effects on sleep disruption, sodium oxybate alone and in combination with modafinil significantly reduced the number of transitions from deep or REM sleep into light sleep or wakefulness. Modafinil alone had no such effect. The improvements in patient-reported sleep quality mirrored the objective data, appearing only in the groups receiving sodium oxybate.

¹⁰

Idiopathic Hypersomnia and Pediatric Use

Narcolepsy is not the only condition that benefits. Idiopathic hypersomnia, a disorder of excessive daytime sleepiness without cataplexy and with its own distinct symptom profile, has historically had no approved treatments. A phase 3 randomized withdrawal study found that patients with idiopathic hypersomnia who were switched from a lower-sodium oxybate formulation to placebo deteriorated significantly, while those who stayed on the drug remained stable. The safety profile was consistent with what had already been seen in narcolepsy patients.

¹¹

Response rates were high. Over 80% of participants achieved a clinically meaningful improvement on a disease-specific severity scale, and up to 98% showed meaningful decreases in symptom scores by the end of the stable-dose period.

¹²

In children and adolescents with narcolepsy, a randomized withdrawal trial showed that stopping sodium oxybate led to a large rebound in cataplexy, with a median increase of nearly 13 additional attacks per week compared to essentially no change in those who continued the drug. Common side effects in children included bedwetting, nausea, vomiting, headache, and weight loss. Two serious psychiatric events, one case of severe acute psychosis and one of moderate suicidal ideation, were judged related to the drug.

¹³

Long-term follow-up of pediatric patients over 48 weeks showed that the cataplexy benefit established during the trial was maintained, and the number of cataplexy-free days per week increased over time. The side effect profile remained similar, dominated by bedwetting, nausea, and decreased appetite.

¹⁴

Dosing Practicalities and Formulation Differences

One of the most frequently discussed aspects of sodium oxybate is the dosing routine, which historically required patients to wake up in the middle of the night to take a second dose. The original approved formulations (effective dose range of 6 to 9 grams per night) are taken as two divided doses: one at bedtime and a second 2.5 to 4 hours later.

¹⁵

This split-dose requirement exists because sodium oxybate is absorbed and eliminated rapidly. A single dose simply does not last long enough to cover a full night of sleep. The need to set an alarm for a middle-of-the-night dose is a significant burden, and many patients find it disruptive. An extended-release once-nightly formulation (marketed as LUMRYZ) was developed to address this. In the phase 3 REST-ON trial, all tested doses of the once-nightly version produced significant improvements across the primary narcolepsy endpoints compared to placebo, and a significantly greater proportion of treated patients were able to stay awake for the full 30 minutes of wakefulness testing.

¹⁶

A separate concern with the original formulation (Xyrem) is its sodium content. At therapeutic doses, patients can ingest several grams of sodium per night, which is problematic for anyone with heart failure, kidney disease, or hypertension. A reformulated version (Xywav) replaces most of the sodium with calcium, magnesium, and potassium ions, cutting the sodium load by 92%.

¹⁷

Side Effects and Safety Concerns

In everyday clinical use, side effects are common enough that about half of patients experience at least one, and roughly a quarter eventually stop taking the drug because of them. The most frequently reported problems are nausea, mood swings, and bedwetting.

¹⁸

Taken alone, sodium oxybate can cause confusion, sleepwalking, hallucinations, and agitation. Respiratory depression is the most dangerous acute risk, and it becomes substantially more likely when the drug is combined with alcohol or other sedatives.

¹⁹

An emerging cardiovascular concern is blood pressure. A study of normotensive narcolepsy patients found that those starting sodium oxybate had more than 50% higher risk of developing new-onset hypertension or needing blood pressure medication compared to non-users. The sodium content of the original formulation likely plays a role here, which is one reason the lower-sodium version was developed. Patients with existing cardiovascular risk factors should be monitored closely.

²⁰

Abuse Potential, Dependence, and the GHB Connection

Sodium oxybate’s identity as the sodium salt of GHB is impossible to ignore. GHB itself is classified as a Schedule I controlled substance in the United States, meaning it has no accepted medical use and high abuse potential. Sodium oxybate, by contrast, is classified as Schedule III, indicating moderate-to-low potential for dependence. This unusual split classification reflects the regulatory compromise that allowed the drug to reach patients: a tightly controlled distribution system (the REMS program) restricts prescribing and dispensing to mitigate the risk of diversion.

²¹

Withdrawal from illicit GHB used at high doses around the clock can be severe. Published case series describe rapid onset of psychosis, severe agitation requiring physical restraint, hallucinations, and cardiovascular instability, with symptoms starting within hours of the last dose and lasting up to two weeks.

²²

At prescribed therapeutic doses for narcolepsy, though, the withdrawal picture looks very different. In a study of 55 narcolepsy patients who had been taking 3 to 9 grams nightly for up to nearly four years, those abruptly switched to placebo reported only minor symptoms like anxiety, dizziness, insomnia, and sleepiness. The researchers noted that these were difficult to distinguish from narcolepsy symptoms simply returning. They concluded there was minimal evidence of a withdrawal syndrome at therapeutic doses.

²³

This is an important distinction that often gets lost. The horror stories about GHB withdrawal come from recreational users taking far higher doses, often multiple times per day. Prescription sodium oxybate at standard doses, taken once or twice nightly, occupies a different pharmacological space. That said, clinicians generally still taper the drug rather than stopping it abruptly, both out of caution and because the underlying narcolepsy symptoms return quickly.

Hormonal and Metabolic Effects

One of the more unexpected findings about sodium oxybate is its influence on growth hormone. Deep slow-wave sleep is naturally the time when the body secretes the most growth hormone, and since sodium oxybate powerfully increases slow-wave sleep, it also amplifies growth hormone release. A study comparing narcolepsy patients and healthy controls found that sodium oxybate significantly increased total 24-hour growth hormone secretion in the narcolepsy group and strengthened the link between growth hormone pulses and deep sleep episodes.

²⁴

This hormonal shift may help explain a clinically observed benefit: weight loss. People with narcolepsy type 1 frequently gain weight after the disease begins, and many become obese. In a retrospective study comparing narcolepsy patients who started sodium oxybate versus those who started modafinil, the sodium oxybate group showed significant decreases in body mass index over time. Women lost an average of about 2.5 BMI points and men about 0.8. Modafinil users showed no comparable change.

²⁵

Whether the weight loss comes from the growth hormone boost, from better sleep quality improving metabolic function, from reduced appetite (a commonly reported side effect), or some combination of all three remains an open question. For patients already struggling with the metabolic consequences of narcolepsy, though, it is a welcome secondary benefit.

Fibromyalgia and the Limits of Off-Label Use

Sodium oxybate’s ability to deepen slow-wave sleep drew the attention of fibromyalgia researchers, since people with fibromyalgia often have measurably disrupted deep sleep and report non-restorative sleep as a core complaint. A randomized, placebo-controlled trial found that sodium oxybate significantly improved pain and sleep quality in fibromyalgia patients, with improvements in pain scores correlating with improvements in sleep measures.

²⁶

A larger international phase 3 trial reinforced these findings. About 42% of patients on the lower dose and 51% on the higher dose achieved at least a 30% reduction in pain, compared to 27% on placebo. Sleep quality scores improved by 20 to 25% in the treatment groups versus essentially no change with placebo.

²⁷

Despite promising trial results, the FDA never approved sodium oxybate for fibromyalgia, citing concerns about the drug’s abuse potential and safety profile in a much larger patient population than narcolepsy. The REMS program that keeps the drug tightly controlled for narcolepsy would be far harder to scale to the millions of people with fibromyalgia. This remains one of the more frustrating chapters in the drug’s story: the evidence of benefit is reasonably solid, but the regulatory and safety math did not work out for broader use.